AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04072731 — intervention group
Intervention type: OTHER
Intervention: pathologic
Description: All the enrolled patients were treated with whole resection and diagnosed by the Pathology Department based on the pathological evidence.
Study NCT01491269 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Internet-based cognitive behavioural treatment
Description: Eight weeks internet-based cognitive behavioural treatment. Treatment consisted of education, cognitive skills acquisition, behavioural rehearsal, generalization and maintenance.
Study NCT02428894 — intervention group
Intervention type: DEVICE
Intervention: LVAD
Study NCT01310244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat, Carboplatin, Paclitaxel
Description: Up to 6 cycles of combination therapy of belinostat plus carboplatin (AUC 6) and paclitaxel 200 mg/m2. Initial dose of belinostat will be 1000mg/m2 for MTD dose escalation evaluation.
Study NCT00493987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Enanthate
Description: testosterone ester
Study NCT00493987 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dutasteride
Description: 5 alpha-reductase inhibitor
Study NCT04346771 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working memory training
Description: Participants complete 10 sessions of maintaining positive working memory training during a two-week period. Each session consists of 15 blocks.
Study NCT04346771 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Positive ABMT
Description: Participants complete 8 sessions of attention bias modification training (ABMT) during a two-week period. Each session consists of 218 trials, and the time to complete a training session is 12 minutes.
Study NCT02234336 — intervention group
Intervention type: PROCEDURE
Intervention: Noncontrast echocardiography
Study NCT02234336 — intervention group
Intervention type: PROCEDURE
Intervention: Contrast Echocardiography
Study NCT02741258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: skin cream
Description: cream to treat skin erythema due to radiotherapy
Study NCT00808899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Temsirolimus
Study NCT00808899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan
Study NCT00808899 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection of Primary Tumor
Description: Surgical Resection of Primary Tumor
Study NCT00808899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide
Study NCT00808899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin
Study NCT00808899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide
Study NCT00808899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin
Study NCT00808899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Topotecan
Study NCT00808899 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PBSC
Description: Peripheral Blood Stem Cell Harvest
Study NCT02234336 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiac magnetic resonance imaging
Study NCT03268512 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: L-PRF
Description: Platelet concentrates are produced from a small peripheral blood sample, which is immediately centrifuged without any anticoagulant. Coagulation starts during the centrifugation, and three layers are obtained: red blood corpuscles (RBCs) at the bottom of the tube, platelet-poor plasma (PPP) on the top and an intermediate layer called buffy coat where most platelets and leucocytes are concentrated. L-PRF has potential advantages, namely: it creates a bioactive construct that stimulates the local environment for differentiation and proliferation of stem and progenitor cells and it acts as an immune regulation node with inflammation control abilities, such as slow continuous release of growth factors over a period of 7-14 days.
Study NCT03268512 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A-PRF
Description: Platelet concentrates are produced from a small peripheral blood sample, which is immediately centrifuged without any anticoagulant. Coagulation starts during the centrifugation, and three layers are obtained: red blood corpuscles (RBCs) at the bottom of the tube, platelet-poor plasma (PPP) on the top and an intermediate layer called buffy coat where most platelets and leucocytes are concentrated. L-PRF has potential advantages, namely: it creates a bioactive construct that stimulates the local environment for differentiation and proliferation of stem and progenitor cells and it acts as an immune regulation node with inflammation control abilities, such as slow continuous release of growth factors over a period of 7-14 days.
Study NCT00475878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram
Description: 10mg escitalopram/day for 3 months
Study NCT00475878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsule/day for 3 months
Study NCT01633086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nitric oxide gel
Description: 1. st gel: sodium nitrites,BID local use X 28 days~2. nd gel: maleic/ascorbic acids ,BID local use X 28 days
Study NCT01633086 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: placebo gel,BID local use X 28 days
Study NCT00552786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Description: 600mg twice daily for 2 weeks
Study NCT00552786 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: glucose
Description: 1 gm glucose capsule
Study NCT00429494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: 22.5 mg IM injection 2 months before transplant and 3 months post-transplant.
Study NCT00429494 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaires taking about 15 minutes to complete.
Study NCT00429494 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Stem Cell Transplantation
Description: Stem cell infusion on Day 0.
Study NCT04263792 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: [18F]fluoropropyl-trimethoprim
Description: \[18F\]Fluoropropyl-Trimethoprim, also known as \[18F\]F-TMP, is a radiolabeled imaging agent for positron emission tomography (PET/CT).The use most relevant to this protocol is for imaging bacterial infection in human subjects. The parent compound, trimethoprim (TMP) is a well-known, safe, broad-spectrum, synthetic, small molecule antibiotic that has been used clinically for over 50 years for the treatment of acute bacterial infection and has been combined with sulfa-based antibiotics (Bactrim/Septra) for bacterial infection prophylaxis especially in the lung and bladder. An immediate clinical use for TMP radiotracers is imaging of pathologic bacteria that are the cause of human infection.
Study NCT02910518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glulisine (U300)
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study NCT02910518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glulisine
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study NCT02910518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: Pharmaceutical form: solution~Route of administration: intravenous/subcutaneous
Study NCT02910518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin aspart
Description: Pharmaceutical form: solution~Route of administration: intravenous/subcutaneous
Study NCT02910518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPH insulin
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study NCT02910518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH insulin
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study NCT02910518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: Pharmaceutical form: Powder and solvent for solution for injection~Route of administration: subcutaneous
Study NCT02910518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Description: Pharmaceutical form: Powder and solvent for solution for injection~Route of administration: subcutaneous
Study NCT02910518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Pharmaceutical form: solution~Route of administration: intravenous
Study NCT02910518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: Pharmaceutical form: solution~Route of administration: intravenous
Study NCT02910518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Pharmaceutical form: solution~Route of administration: intravenous
Study NCT02910518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Pharmaceutical form: solution~Route of administration: intravenous
Study NCT00933842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LACTIC ACID(ND)
Description: Treatment duration: 5 weeks
Study NCT03289481 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active lozenge
Description: nitric oxide generating lozenge
Study NCT03289481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo tablet
Study NCT04472780 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen Therapy HBOT
Description: HBOT therapy protocol: in an eight-seat hyperbaric chamber 40 sessions of HBOT duration: 1 hour rhythm: 5 sessions / week pressure: 1.7 ATA (7 meters) O2 concentration: 100%
Study NCT03935217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secnidazole
Description: Oral Granules containing secnidazole
Study NCT03935217 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Granules of placebo manufactured to mimic secnidazole
Study NCT00259376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronedarone (SR33589)
Description: oral administration
Study NCT00259376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: oral administration
Study NCT01992549 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human-cl rhFVIII
Study NCT04198740 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tear sample collection via Schirmer strip and subsequent analysis by mass spectrometry
Description: During regular consultations at the ophthalmology department of the CHUM, eligible patients will undergo a standard 5 minute Schirmer tear test. The Schirmer strips will serve as tear samples and will be sent to UQAM's Department of chemistry for mass spectrometry analysis.
Study NCT03507543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP4297
Description: The dose levels will be escalated following a modified 3+3 dose escalation scheme.
Study NCT00268931 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Movement Training
Description: This group of infants underwent specific movement training activities two times per day with their parents.
Study NCT00268931 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Training
Description: This group underwent special social interactions with their parents two times each day.
Study NCT00896129 — intervention group
Intervention type: OTHER
Intervention: HRQOL Survey Packet
Description: Questionnaires
Study NCT05980429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy, prescribed
Description: All music pieces selected for the prescribed intervention contain compositional elements of relaxation analyzed, prepared, and recorded by professional concert artists and a Grammy-nominated composer. The compositional elements included Accentuation, Articulation, Dynamic Range, Familiarity, Interpretive Expertise, Melodic Shape, Meter, Recording Quality, Repetition, Register, Rubato, Tempo, Texture, Timbre, Transition, and Tonality. These 15 repertoire-selecting parameters were used to choose the prescribed music play list for this study. Music used for the study was downloaded from a password-protected Google Drive accessible to the study participants assigned to the prescribed music intervention group.
Study NCT05980429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy, self-selected
Description: All music pieces were self-selected by the participant
Study NCT04444375 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: balance test
Description: balance test
Study NCT03765463 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habit Reversal Training
Description: 4 sessions of habit reversal training
Study NCT02044237 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decoupling
Study NCT02044237 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive relaxation
Study NCT00991159 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RN316
Description: Single, escalating doses of RN316 administered IV. Doses planned for testing = 0.3, 1.0, 3.0, 6.0, 12.0, and 18.0 mg/kg.
Study NCT00808899 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation Therapy
Study NCT00808899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13-cis-retinoic acid
Description: 13-cis-retinoic acid
Study NCT02547597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Study NCT02547597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol
Study NCT01687868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: dexmedetomidine 0.7mcg/kg/hr continuous infusion
Study NCT00099203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate [Bondronat]
Description: 6mg iv on days 1-3, and every 3-4 weeks
Study NCT00099203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zoledronic acid
Description: 4mg iv on day 1 and every 3-4 weeks
Study NCT03181282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Postural stability exercises will follow a framework targeting quiet stance, anticipatory and reactive postural adjustments, and dynamic postural control. Gait exercises will include treadmill walking and practice with dual-task gait. A home exercise program (HEP), to be completed twice weekly, will be provided on each participant's initial visit with the physical therapist following STN-DBS surgery. The HEP will include the following exercises: trunk rotation, standing hip flexion, standing hip abduction, standing plantarflexion, and standing squat.
Study NCT02413606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced follow-up schedule
Description: In the intervention group, the follow-up schedule will be limited to four follow-up visits at 3, 12, 24 and 36 months, under the specific condition that patients have easy and prompt access to care (specialised nurse of gynaecologist) if symptoms or questions occur. The content of the follow-up visits will be similar for both groups.
Study NCT03561597 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile health intervention
Description: The Kurbo program is a multifunctional mobile application that aid adolescents and their families to learn healthy eating habits and weight management through the use of a mobile application with dietary self-monitoring and weekly interactive coaching sessions. Using the Kurbo app, adolescents track their food and exercise, as well as learn about healthy behaviours through games and videos. The Kurbo coaches check in with adolescents for 15 minutes once a week via video, phone or text over a 12 weeks period.
Study NCT04297072 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY-597939)
Description: Non-vitamin K antagonist oral anticoagulants (NOACs). The prescription of drug is at the discretion of physician following the routine clinical practice.
Study NCT04297072 — intervention group
Intervention type: DRUG
Intervention: VKAs
Description: Oral anticoagulant. The prescription of drug is at the discretion of physician following the routine clinical practice.
Study NCT00573651 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood Draws for Serum Titers
Description: All study subjects are receiving the Gardasil vaccine as part of their clinical care. The Gardasil vaccine is not given because of study participation. The study observes outcomes related to this clinical care. Study intervention consists of some blood samples taken to measure antibody and RNA titers. Other study specific procedures performed include Questionnaires and observational data.
Study NCT00331708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate plus sulfadoxine-pyrimethamine
Study NCT03765164 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: GlycoMark 1-5-AG
Description: Online educational materials on GlycoMark 1,5-AG and sample test results for simulated patients
Study NCT03765164 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Performance and Value Vignettes
Description: Simulated diabetic patients cared for online
Study NCT03765164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Performance and Value Vignettes
Description: Simulated diabetic patients cared for online
Study NCT02484547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aducanumab (BIIB037)
Description: Low dose
Study NCT02484547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aducanumab (BIIB037)
Description: High dose
Study NCT02484547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT01351337 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: diffusion tensor tractography neuronavigation and intraoperative subcortical stimulation
Description: All of the patients underwent tumor resection assisted with combined use of Diffusion tensor tractography-integrated functional neuronavigation and intraoperative subcortical stimulation
Study NCT02894905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-335
Description: Participants with various degrees of impaired renal function (mild \[Cohort 1\], moderate \[Cohort 2\], severe \[Cohort 3\]) and normal renal function (Cohort 4) will receive a single oral dose of AL-335 800 mg (given as 2\*400-mg tablets).
Study NCT00815919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given intravenously at a dose of 1.3 mg/m\^2 once a week for the first four weeks of a five week cycle for a total of 3 cycles
Study NCT00815919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Taken orally once a day at a dose of 0.5-1 mg/kg. Dose reduction may be initiated after 1 cycle of therapy. A suggested taper is 10-25% every 1-2 weeks.
Study NCT05930132 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: submucosal conchoplasty
Description: Regarding the submucosal conchoplasty technique, the concha was locally infiltrated with adrenaline with a concentration of 1:200,000. The mucosa was incised by blade 15 starting from the axilla posteriorly up to the attachment with the basal lamella. The mucosa covering the lateral lamella was dissected using the freer dissector. The lateral lamella was removed using a through cut forceps then the mucosa was repositioned. The bony skeleton of the medial lamella was preserved
Study NCT05930132 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: classic lateral lamellectomy
Description: Regarding the lateral lamellectomy technique, the concha was locally infiltrated with adrenaline with a concentration of 1:200,000; the sickle knife was used to open the concha then the scissor was used to remove the lateral lamella with its covering mucosa in one block.~No middle meatus packing was applied. Systemic antibiotics and steroids (0.5 mg / kg prednisolone) were given for two weeks after the surgery. The patients were instructed to use local nasal irrigations (2 ml of budesonide 0.5 mg / ml mixed with 250 ml of normal saline) two times daily for a month postoperatively. Patients were followed up at the end of each month throughout the six months follow-up period.
Study NCT00546078 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix™
Description: Intramuscular injection, one or three doses
Study NCT00814645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Nitrite Inhalation Solution
Description: a single dose of AIR001 Inhalation Solution administered by inhalation following nebulization
Study NCT00814645 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and AIR001 Inhalation Solution (Expansion arm)
Description: On Day 1, subjects will receive a single placebo-form dose of inhaled nebulized AIR001 Inhalation Solution (containing diluent and excipient solutions alone). On Day 2, the same subjects will receive a single administration of AIR001 Inhalation Solution at the minimum pharmacologically active and safe dose identified from dose levels 1-4. Subjects will be blinded to the treatment schema.
Study NCT04637516 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Animation program BlinkBlink
Description: Computer program that presents horizontal bars on the computer screen that move from above and below towards each other, mimicking a blink movement.